New Avenues in Hypertension

Registration & Breakfast @ 8:00 AM (CT) (Breakfast provided).

Prefer to participate online? Register for our livestream at ExchangeCME.com/HTNashvilleVirtual

Program Description

This Mechanism to Medicine symposium will explore the evolving management of uncontrolled and resistant hypertension, with a focus on the underlying pathophysiology driving disease progression and treatment resistance. Expert faculty will review the role of the renin-angiotensin-aldosterone system, the clinical evidence for approved and emerging therapies, including aldosterone synthase inhibitors, and the latest recommendations for individualized patient care. Through case-based discussions, participants will gain practical strategies to optimize treatment selection and improve blood pressure control in patients with uncontrolled and resistant hypertension.

Target Audience

This educational activity has been designed to educate primary care providers (PCPs), internal medicine clinicians, and other healthcare providers (HCPs) who manage patients with hypertension.

Educational Objectives

Upon completion of this activity, participants will be better prepared to:

1. Explain the pathophysiologic roles of the renin-angiotensin-aldosterone system in hypertension, including contributions to uncontrolled and resistant disease and implications for new therapies
2. Discuss the clinical profiles and evidence for new therapies, including aldosterone synthase inhibitors, in the treatment of uncontrolled and resistant hypertension
3. Individualize therapeutic regimens for uncontrolled and resistant hypertension based on appropriate case identification, recommended blood pressure targets, treatment responses, and patient-specific risks 

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Credit Information

The AAFP has reviewed New Avenues in Hypertension: Evolving Management of Uncontrolled and Resistant Disease and deemed it acceptable for up to 1.50 Live AAFP Prescribed credit(s). Term of Approval is from 10/20/2026 to 10/20/2026. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation. 

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

• John M. Flack, MD, MPH: Research: Verve, Boston Scientific, Recor, Astra Zeneca, Novo Nordisk, Idorsia, Mineralys; Consulting: Georges Medicine, Azurity, Astra Zeneca, Boston Scientific, Casana, Idorsia,Mineralys, Regor Therapuetics; Data Safety and Monitoring Board: CRISPR Therapeutics; Royalties: UptoDate; Expert Witness: Teva
• Kausik Umanath, MD, MS, FACP, FASN: Contracted Research: AstraZeneca, ICON/Lilly, ICON/Novo Nordisk
• Karol Watson MD, PhD: Consulting Fees: Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Regeneron
• Chuck Vega, MD, FAAFP: Consulting Fees: Boehringer Ingelheim, Exact Sciences, GSK

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this activity.

Integritas Contact Information

For information about this program, please contact us at info@exchangecme.com.